Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Apr;77(4):473-475.
doi: 10.1136/annrheumdis-2017-212376. Epub 2018 Jan 6.

Adalimumab concentration-based tapering strategy: as good as the recommended dosage

Denis Mulleman  1 , Alejandro Balsa  2
Affiliations
Editorial

Adalimumab concentration-based tapering strategy: as good as the recommended dosage

Denis Mulleman et al. Ann Rheum Dis. 2018 Apr.
No abstract available

Keywords: anti-TNF; rheumatoid arthritis; treatment.

PubMed Disclaimer

Conflict of interest statement

Competing interests: AB has received unrestricted grants from Pfizer, Roche and AbbVie and speaker fees from Pfizer, AbbVie, MSD, BMS, UCB, Novartis, Sandoz, Celltrion and Roche, and has acted as a consultant for Pfizer, Sandoz, Nordic, AbbVie, Roche, BMS, UCB and MSD. DM participated on behalf of his institution in clinical trials sponsored by AbbVie, Roche, BMS, Pfizer, UCB and MSD; his hospital received a grant for research from AbbVie in 2004 and from Nordic Pharma in 2012; he has acted as a consultant and given lectures on behalf of his institution for MSD, Novartis, UCB and Pfizer; he has been invited to attend international congresses by MSD, Roche, BMS, AbbVie and Janssen-Cilag.

Comment on

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Paintaud G, Passot C, Ternant D, et al. . Rationale for therapeutic drug monitoring of biopharmaceuticals in inflammatory diseases. Ther Drug Monit 2017;39:339–43. 10.1097/FTD.0000000000000410 - DOI - PubMed
    1. l’Ami MJ, Krieckaert CL, Nurmohamed MT, et al. . Successful reduction of overexposure in patients with rheumatoid arthritis with high serum adalimumab concentrations: an open-label, non-inferiority, randomised clinical trial. Ann Rheum Dis 2018;77:484–7. 10.1136/annrheumdis-2017-211781 - DOI - PubMed
    1. Pouw MF, Krieckaert CL, Nurmohamed MT, et al. . Key findings towards optimising adalimumab treatment: the concentration-effect curve. Ann Rheum Dis 2015;74:513–8. 10.1136/annrheumdis-2013-204172 - DOI - PubMed
    1. Vogelzang EH, Kneepkens EL, Nurmohamed MT, et al. . Anti-adalimumab antibodies and adalimumab concentrations in psoriatic arthritis; an association with disease activity at 28 and 52 weeks of follow-up. Ann Rheum Dis 2014;73:2178–82. 10.1136/annrheumdis-2014-205554 - DOI - PubMed
    1. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. . Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007;66:921–6. 10.1136/ard.2006.065615 - DOI - PMC - PubMed